GlassScriptPhysician profile
Marc O Anderson
NPI 1154307197
$7,632.77
in general payments reported to CMS, 2019-2025
57 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $768 · 2021: $1,008 · 2022: $1,018 · 2023: $2,525 · 2024: $913 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729 · Travel and Lodging: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.25 |
| Travel and Lodging | $962.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,496.71 | 2023 | |
| Lilly USA, LLC | $625.02 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $514.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $489.29 | 2020-2024 | Vraylar, Ubrelvy |
| Amgen INC. | $470.66 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.73 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Pfizer INC. | $398.67 | 2019-2023 | |
| Glaxosmithkline, LLC. | $385.95 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $345.48 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $315.69 | 2020-2024 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $227.37 | 2019-2022 | |
| Amarin Pharma, INC. | $217.89 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $189.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $154.00 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dynavax Technologies Corporation | $105.43 | 2019-2024 | Heplisav-B |
Show all 53 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.